CELF2 and breast carcinoma: The better prognosis in breast cancer (overall survival (OS): HR = 0.5, 95% CI = 0.38 to 0.65, log‐rank p = 2.6e‐7; relapse‐free survival (RFS): HR = 0.42, 95% CI = 0.36 to 0.49, log‐rank p < 1e‐16) and lung cancer (OS: HR = 0.51, 95% CI = 0.42 to 0.61, log‐rank p = 2.1e‐12; progression‐free survival (PFS): HR = 0.44, 95% CI = 0.31 to 0.63, log‐rank p = 3.6e‐6) was shown in patients with higher CELF2 expression (Figure 2M–P).